Abstract
Background and Aims: Severe hypertriglyceridemia (sHTG; fasting triglycerides ≥500 mg/dL) is a causal risk factor for acute pancreatitis. This phase 2 study (NCT03452228) evaluated efficacy and safety of evinacumab, an investigational angiopoietin-like protein 3 inhibitor, in patients with sHTG who had ≥1 prior hospitalization for acute pancreatitis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
